Literature DB >> 24469010

[Treatment of lipid disorders].

F Custodis1, U Laufs.   

Abstract

Lipid disorders play an essential role in the pathogenesis of atherosclerotic diseases. An integral part of the clinical evaluation is the estimation of the individual cardiovascular risk using risk scores and patient history. Due to the long established prognostic relevance, reduction of low-density lipoproteins (LDL) using statins remains beyond doubt the central intervention both in primary and secondary prevention of atherosclerotic diseases. Indispensible components of treatment in all patients with elevated triglyceride levels are lifestyle changes contributing to a reduction of accompanying risk factors, in particular physical activity and smoking cessation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24469010     DOI: 10.1007/s00059-013-4013-x

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  29 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Authors:  Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood
Journal:  Eur Heart J       Date:  2011-06-28       Impact factor: 29.983

3.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

4.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.

Authors:  Allen J Taylor; Lance E Sullenberger; Hyun J Lee; Jeannie K Lee; Karen A Grace
Journal:  Circulation       Date:  2004-11-10       Impact factor: 29.690

5.  Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia.

Authors:  R H Knopp; H Gitter; T Truitt; H Bays; C V Manion; L J Lipka; A P LeBeaut; R Suresh; B Yang; E P Veltri
Journal:  Eur Heart J       Date:  2003-04       Impact factor: 29.983

Review 6.  Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk.

Authors:  Molly C Carr; John D Brunzell
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

Review 7.  New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs.

Authors:  Giuseppe Danilo Norata; Christie M Ballantyne; Alberico Luigi Catapano
Journal:  Eur Heart J       Date:  2013-03-18       Impact factor: 29.983

8.  Haemodialysis-induced transient CD16+ monocytopenia and cardiovascular outcome.

Authors:  Kyrill S Rogacev; Maren Ziegelin; Christof Ulrich; Sarah Seiler; Matthias Girndt; Danilo Fliser; Gunnar H Heine
Journal:  Nephrol Dial Transplant       Date:  2009-07-08       Impact factor: 5.992

9.  Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies.

Authors:  Nadeem Sarwar; John Danesh; Gudny Eiriksdottir; Gunnar Sigurdsson; Nick Wareham; Sheila Bingham; S Matthijs Boekholdt; Kay-Tee Khaw; Vilmundur Gudnason
Journal:  Circulation       Date:  2006-12-26       Impact factor: 29.690

10.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Authors:  C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.